SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1982)12/17/2003 10:55:50 PM
From: hmpa  Respond to of 3044
 
Orphan status precludes marketing by the competitor into an indication (as per label, formal advertising - both to physicians and DTC). Generic companies generally don't do marketing other than to PBMs. I never heard about indication exclusivities stopping generic erosion for any drug once the key patents expire or are thrown out. Likes of Mylan or Barr together with MM patient community will force CELG to allow generic product into STEPS.



To: Biomaven who wrote (1982)12/18/2003 12:38:34 AM
From: Madharry  Respond to of 3044
 
I am confused perhaps about the fda answer- it sounds as if the generic competitor could not be marketed for an additional indication for which orphan drug status was granted- does this mean that a physician would not be able to prescribe a signficantly cheaper generic product for the alternative indication?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News